H. Kim Lyerly

DCI oncologists and researchers are supporting the Komen mission “for a cure” — fighting breast cancer on all fronts. Learn about their research.

A vaccine for HER2-positive breast cancers that is being tested in a clinical trial at DCI is part of an effective, two-drug strategy for enlisting the immune system to fight tumors.

Lyerly, Hartman spinout company Replicate Bioscience and Immunomic Therapeutics form collaboration to combat infectious diseases and cancers.

Here's a sample of some of the DCI physicians, physician-scientists, researchers and nurses whose work is featured by the media and in academic journals.

DCI researchers have observed how stem cell mutations quietly arise and spread throughout a widening field of the colon until they eventually predominate and become a malignancy.     

The mainstay drug trastuzumab could benefit from another antibody to remove roadblocks.